For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as well.What are the Zacks Style Scores?The Z ...

Merck (MRK) announced that the phase III KEYLYNK-006 study, evaluating the combination of its blockbuster drugs Keytruda and Lynparza in certain non-small cell lung cancer (NSCLC) patients, failed to meet its primary endpoints.The KEYLYNK-006 study evaluated Keytruda, combined with Lynparza as maintenance therapy, for the first-line treatment for patients with metastatic non-squamous NSCLC with no EGFR, ALK or ROS1 genomic tumor aberrations. Patients in the control group received pemetrexed chemotherapy ins ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive data from multiple Phase 3 studies evaluating V116, the company’s investigational, adult-specific 21-valent pneumococcal conjugate vaccine, at the 13th Meeting of the International Society of Pneumonia and Pneumococcal Diseases (ISPPD) in Cape Town, South Africa. Across the clinical studies presented, V116 was shown to be immunogenic for all 21 serotypes covered by the vaccine in ...

Cutting edge & AI solution for continuous and precise monitoring of individual swine weight HOD HASHARON, Israel, March 15, 2024 /PRNewswire/ -- FarmSee, a pioneer in camera-based Artificial Intelligence ("AI") solutions for swine monitoring and production optimization, is excited to announce a strategic collaboration with MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK).  MSD Animal Health, a biopharmaceuticals and technology solutions company, has participated in FarmSee's ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemoradiotherapy (CRT) met its primary endpoint of overall survival (OS) for the treatment of newly diagnosed patients with high-risk locally advanced cervical cancer. At a pre-specified interim analysis conducted by an independent Data Monitoring ...

In the latest trading session, Merck (MRK) closed at $120.51, marking a -1.35% move from the previous day. The stock fell short of the S&P 500, which registered a loss of 0.29% for the day. At the same time, the Dow lost 0.35%, and the tech-heavy Nasdaq lost 0.3%.The the stock of pharmaceutical company has fallen by 2.91% in the past month, lagging the Medical sector's gain of 3.72% and the S&P 500's gain of 4.42%.The investment community will be paying close attention to the earnings performance of Merck i ...

The most recent trading session ended with Merck (MRK) standing at $122.16, reflecting a -0.41% shift from the previouse trading day's closing. This change lagged the S&P 500's 0.19% loss on the day. Elsewhere, the Dow saw an upswing of 0.1%, while the tech-heavy Nasdaq depreciated by 0.54%.The pharmaceutical company's shares have seen a decrease of 2.21% over the last month, not keeping up with the Medical sector's gain of 2.91% and the S&P 500's gain of 3.18%.The investment community will be paying close ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today, at the EUROGIN 2024 HPV Congress, announced plans to initiate clinical development of a new investigational multi-valent HPV vaccine designed to provide broader protection against multiple HPV types. Separately, the company also plans to conduct clinical trials in both females and males to evaluate the efficacy and safety of a single-dose regimen of GARDASIL®9 (Human Papillomavirus 9-valent, recomb ...

Merck & Co., Inc. (NYSE:MRK) Barclays 26th Annual Global Healthcare Conference March 12, 2024 3:05 PM ET Company Participants Jannie Oosthuizen - President, Human Health U.S. Peter Dannenbaum - Vice President, Investor Relations Conference Call Participants Carter Gould - Barclays Carter Gould Good afternoon and welcome to Day One of the Barclays Global Healthcare Conference. My name is Carter Gould, covering U.S. Biopharma. I'm pleased to welcome Merck to the stage. Merck is one of our top picks to start t ...

Merck & Co., Inc. (NYSE:MRK) Leerink Partners 2024 Global Biopharma Conference Call March 11, 2024 12:40 PM ET Company Participants Marjorie Green - SVP and Head of Oncology Peter Dannenbaum - VP, IR Conference Call Participants Daina Graybosch - Leerink Partners Daina Graybosch Hi, everyone. Thank you for coming to the session. My name is Daina Graybosch. I and my team cover immuno-oncology and beyond here at Leerink Partners. And I'm really excited to have a great oncology conversation with Merck. We have ...